A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of VI-1121 in Subjects With Alzheimer's Disease.
Phase of Trial: Phase II
Latest Information Update: 10 Dec 2013
At a glance
- Drugs VI 1121 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- 04 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 08 Nov 2012 Planned end date changed from 1 Jun 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 08 Nov 2012 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.